GTx, Inc. (NASDAQ:GTXI) posted its earnings results on Monday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

GTx (NASDAQ:GTXI) traded up 0.17% on Tuesday, hitting $5.73. 1,093 shares of the stock were exchanged. The company has a 50-day moving average price of $5.52 and a 200 day moving average price of $4.89. The company’s market capitalization is $91.91 million. GTx has a 1-year low of $0.53 and a 1-year high of $11.19.

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at

Separately, ValuEngine upgraded shares of GTx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th.

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Earnings History for GTx (NASDAQ:GTXI)

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with's FREE daily email newsletter.